The CRO contracts held by the Company as of December 31, 2013, are summarized as follows (in thousands):
|
Indication |
Total Contract Amount Remaining as of December 31, 2013 |
Months Remaining on Contract |
||||||
|
HER2 Mutation Positive Solid Tumor (5201) |
$ | 3,560 | 32 | |||||
|
HER2 Mutuant Non-Small Cell Lung Cancer (4201) |
5,060 | 28 | ||||||
|
HER2 Overexpressed/Amplified Breast Cancer (Licensor Legacy Clinical Trials) |
18,389 | 15 | ||||||
|
HER2 Plus Metastatic Breast Cancer (1301) |
46,477 | 43 | ||||||
|
Metastatic HER2-Amplified or Triple-Negative Breast Cancer (10-005) |
1,399 | 36 | ||||||
|
|
|
|||||||
| $ | 74,885 | |||||||
|
|
|
|||||||